PRAGUE-7 - PRAGUE-7

Description:

The goal of the trial was to evaluate the effect of routine upfront use of the GP IIb/IIIa inhibitor abciximab compared with standard peri-procedural abciximab therapy among patients with cardiogenic shock undergoing primary percutaneous coronary intervention (PCI).